Boc-4,5-dehydro-Leu-OH · DCHA

Boc-4,5-dehydro-Leu-OH · DCHA is a Boc-protected dehydro-leucine amino acid derivative provided as a dicyclohexylamine (DCHA) salt, combining an N-Boc peptide synthesis handle with an unsaturated side-chain motif that can influence peptide conformation and reactivity during downstream assembly. The product is commonly used in peptide chemistry workflows where a constrained, non-standard leucine analog is required for structure-property studies, fragment synthesis, and the preparation of modified peptide intermediates. Its salt form is selected to support practical handling and consistent performance in peptide building-block workflows.

1. Modified Peptide Synthesis

Boc-4,5-dehydro-Leu-OH · DCHA is used by peptide chemists to incorporate a dehydro-leucine residue into custom peptides and peptide libraries, enabling access to non-proteinogenic analogs for conformational and structure-activity relationship studies. The N-Boc protection supports standard peptide assembly strategies, while the 4,5-dehydro motif provides a distinct side-chain unsaturation compared with saturated leucine, which can be leveraged when designing peptides with altered backbone/side-chain geometry. Researchers developing peptide fragments for subsequent coupling steps often select this building block because it integrates directly into protected-amino-acid workflows used for rapid synthesis of modified sequences.

2. Peptide Fragment And Intermediate Building

Boc-4,5-dehydro-Leu-OH · DCHA is frequently employed in the preparation of protected peptide fragments and advanced intermediates for solution-phase or stepwise segment condensation workflows. Because the compound is supplied as an N-Boc amino acid derivative, it functions as a reliable monomeric unit for building sequence-defined intermediates that can be carried forward into larger constructs. Medicinal chemistry and process development teams use such intermediates to streamline the synthesis of non-natural peptide components, particularly when the dehydro-leucine residue is needed as a defined structural element for downstream derivatization, purification, or final assembly.

3. Conformational Probe Development

Boc-4,5-dehydro-Leu-OH · DCHA is used in chemical biology and peptide research programs that require non-standard amino acid content to act as a conformational probe within peptide scaffolds. The unsaturated 4,5-dehydro side-chain provides a structural perturbation relative to natural leucine, supporting studies that evaluate how local geometry impacts peptide folding tendencies, aggregation behavior, and recognition by binding partners in vitro. Teams conducting structure-focused peptide design often choose this building block to introduce a defined, residue-level modification that can be compared across analog series while maintaining a protected, synthesis-friendly format for consistent incorporation.

4. Pharmaceutical Intermediate Research

Boc-4,5-dehydro-Leu-OH · DCHA is also applied in pharmaceutical intermediate development when non-natural amino acid derivatives are needed as defined inputs for constructing peptide-like candidates, peptidomimetics, or key synthetic fragments. Process and synthetic chemistry groups use the N-Boc protected form to maintain compatibility with protected-building-block supply chains and to support scalable intermediate handling during route development. The DCHA salt form is selected for practical reagent management in industrial and contract synthesis environments, where consistent physical form and handling characteristics can matter during multistep assembly of specialized peptide intermediates.

1. A possible role of tachykinin-related peptide on an immune system activity of mealworm beetle, Tenebrio molitor L

2. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

3. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

4. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

5. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII